SGMO - Sangamo Therapeutics: Lost In Transition From Lab To Clinic February, 24 2022 11:59 AM Sangamo Therapeutics Inc. SGMO, once an R&D powerhouse, hasn't been able to validate its platform with its clinical data. Its Hemophilia A durability data was underwhelming. I will stay on the sidelines until I see platform validation. For further details see: Sangamo Therapeutics: Lost In Transition From Lab To Clinic